1. Home
  2. ATYR vs CAC Comparison

ATYR vs CAC Comparison

Compare ATYR & CAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • CAC
  • Stock Information
  • Founded
  • ATYR 2005
  • CAC 1875
  • Country
  • ATYR United States
  • CAC United States
  • Employees
  • ATYR N/A
  • CAC N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • CAC Major Banks
  • Sector
  • ATYR Health Care
  • CAC Finance
  • Exchange
  • ATYR Nasdaq
  • CAC Nasdaq
  • Market Cap
  • ATYR 535.0M
  • CAC 629.3M
  • IPO Year
  • ATYR 2015
  • CAC 1997
  • Fundamental
  • Price
  • ATYR $5.63
  • CAC $40.19
  • Analyst Decision
  • ATYR Strong Buy
  • CAC Buy
  • Analyst Count
  • ATYR 5
  • CAC 3
  • Target Price
  • ATYR $23.25
  • CAC $48.00
  • AVG Volume (30 Days)
  • ATYR 4.3M
  • CAC 55.3K
  • Earning Date
  • ATYR 11-06-2025
  • CAC 10-28-2025
  • Dividend Yield
  • ATYR N/A
  • CAC 4.19%
  • EPS Growth
  • ATYR N/A
  • CAC 4.80
  • EPS
  • ATYR N/A
  • CAC 3.11
  • Revenue
  • ATYR N/A
  • CAC $197,501,000.00
  • Revenue This Year
  • ATYR $478.72
  • CAC $42.11
  • Revenue Next Year
  • ATYR $1,899.26
  • CAC $5.51
  • P/E Ratio
  • ATYR N/A
  • CAC $12.88
  • Revenue Growth
  • ATYR N/A
  • CAC 21.74
  • 52 Week Low
  • ATYR $1.67
  • CAC $34.53
  • 52 Week High
  • ATYR $7.29
  • CAC $50.07
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 58.33
  • CAC 52.45
  • Support Level
  • ATYR $5.08
  • CAC $39.82
  • Resistance Level
  • ATYR $5.77
  • CAC $40.77
  • Average True Range (ATR)
  • ATYR 0.42
  • CAC 0.83
  • MACD
  • ATYR 0.02
  • CAC 0.01
  • Stochastic Oscillator
  • ATYR 66.67
  • CAC 40.44

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About CAC Camden National Corporation

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

Share on Social Networks: